Insilico Rentosertib Phase III IPF First Patient
Analysis based on 6 articles · First reported Sep 10, 2026 · Last updated Sep 10, 2026
The milestone reinforces Insilico Medicine's position as a leader in AI-driven drug discovery and could support its share price, which trades on the Hong Kong Stock Exchange, by advancing the first generative AI-discovered drug into late-stage clinical testing. Positive sentiment may spill over to the broader AI-biotech sector and Insilico's collaboration partners, though the drug remains investigational and approval is reportedly three to four years away, limiting near-term revenue impact.
Insilico Medicine announced on September 9-10, 2026 that it has dosed the first patient with Rentosertib (ISM001-055 / INS018_055) in GENESIS-IPF-3, a Phase III clinical trial for idiopathic pulmonary fibrosis (IPF), at United Medical College Hospital, while Shanghai Pulmonary Hospital enrolled its first patient on the same day. The trial is a prospective, multi-center, randomized, double-blind, placebo-controlled, parallel-group study evaluating once-daily Rentosertib over 52 weeks, expected to enroll 320 participants across 47 centers in China, with the primary endpoint being the annual rate of decline in forced vital capacity. The study is led by Professor Zuojun Xu of United Medical College Hospital as Leading Principal Investigator, with Academician Nanshan Zhong and President Chang Chen as Co-Leading Principal Investigators. Rentosertib is described as the world's first drug candidate discovered and developed using generative AI, targeting TNIK, a fibrosis-related pathway identified through AI-driven discovery. Earlier Phase IIa results showed promising dose-dependent improvements in lung function, and the Phase III study aims to validate these findings in a larger cohort over a longer duration. Regulatory approval could reportedly take three to four years under favorable conditions. Insilico also reported first-half 2026 revenue of approximately $106 million, a 287% year-over-year increase, and its first profitable half-year since listing, with adjusted net profit exceeding $51 million, driven by collaborations with partners including Eli Lilly and Company, Laboratoires Servier, Takeda Pharmaceutical Company, SK Biopharmaceuticals, Qilu Pharmaceutical, Hygeia Therapeutics, CMS, and Tenacia. The U.S. United States — Food and Drug Administration granted Orphan Drug Designation to Rentosertib for IPF in February 2023. Insilico Medicine is listed on the Hong Kong Stock Exchange under stock code 3696.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard